Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of zonisamide as adjunctive therapy for myoclonic seizures in idiopathic generalized epilepsy
2007-006696-36Phase 3Terminated
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of zonisamide in Genetic generalized epilepsy (GGE) and myoclonic epilepsies, sponsored by Eisai Co., Ltd. Primary endpoints: Long-term safety of zonisamide and Long-term maintenance of efficacy. Started Aug 2008; status: terminated.
02
Drugs
zonisamide
03
Conditions
Genetic generalized epilepsy (GGE)myoclonic epilepsies
Beyond the preview
Go deeper on 2007-006696-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006696-36.